{
    "ticker": "APRE",
    "name": "Aprea Therapeutics, Inc.",
    "description": "Aprea Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. Founded in 2011, Aprea is dedicated to advancing the understanding and treatment of cancer through its proprietary platform targeting the p53 tumor suppressor protein. The company\u2019s lead product candidate, APR-246, is designed to restore the function of mutant p53, a common mutation found in various cancers that leads to uncontrolled cell growth and proliferation. Aprea's pipeline includes clinical and preclinical programs that aim to leverage the p53 pathway to enhance the efficacy of existing treatments and provide new options for patients with hematologic malignancies and solid tumors. The company's commitment to scientific excellence is reflected in its collaborations with leading academic institutions and research organizations, which help drive innovation and expedite the development of its therapeutic candidates. With a strong focus on addressing unmet medical needs, Aprea Therapeutics is poised to significantly impact the future of cancer treatment and improve patient outcomes through targeted therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boston, Massachusetts, USA",
    "founded": "2011",
    "website": "https://www.apreatx.com",
    "ceo": "Hamza Suria",
    "social_media": {
        "twitter": "https://twitter.com/ApreaTx",
        "linkedin": "https://www.linkedin.com/company/aprea-therapeutics/"
    },
    "investor_relations": "https://investors.apreatx.com",
    "key_executives": [
        {
            "name": "Hamza Suria",
            "position": "CEO"
        },
        {
            "name": "Gregory K. F. Lee",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "APR-246"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aprea Therapeutics, Inc. | Innovative Cancer Therapies",
        "meta_description": "Aprea Therapeutics, Inc. is focused on developing innovative cancer therapies targeting the p53 pathway. Learn about our lead product APR-246 and our commitment to improving patient outcomes.",
        "keywords": [
            "Aprea Therapeutics",
            "APR-246",
            "cancer therapy",
            "biotechnology",
            "p53",
            "oncology"
        ]
    },
    "faq": [
        {
            "question": "What is Aprea Therapeutics known for?",
            "answer": "Aprea Therapeutics is known for developing innovative cancer therapies, particularly those targeting the p53 tumor suppressor protein."
        },
        {
            "question": "Who is the CEO of Aprea Therapeutics?",
            "answer": "Hamza Suria is the CEO of Aprea Therapeutics, Inc."
        },
        {
            "question": "Where is Aprea Therapeutics headquartered?",
            "answer": "Aprea Therapeutics is headquartered in Boston, Massachusetts, USA."
        },
        {
            "question": "What is Aprea's lead product candidate?",
            "answer": "Aprea's lead product candidate is APR-246, designed to restore the function of mutant p53."
        },
        {
            "question": "When was Aprea Therapeutics founded?",
            "answer": "Aprea Therapeutics was founded in 2011."
        }
    ],
    "competitors": [
        "BMY",
        "MRNA",
        "GILD",
        "AMGN"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "RHHBY",
        "NVS"
    ]
}